Charles River Laboratories International, Inc. Stock price

Equities

CRL

US1598641074

Biotechnology & Medical Research

Delayed Nyse 04:00:01 2023-10-02 pm EDT Intraday chart for Charles River Laboratories International, Inc. 5-day change 1st Jan Change
193.39 USD -1.32% -2.12% -11.25%
Sales 2023 * 4,135 M Sales 2024 * 4,352 M Capitalization 10 048 M
Net income 2023 * 399 M Net income 2024 * 467 M EV / Sales 2023 *
2,96x
Net Debt 2023 * 2,196 M Net Debt 2024 * 1,773 M EV / Sales 2024 *
2,72x
P/E ratio 2023 *
25,6x
P/E ratio 2024 *
22,1x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float98.18%
More Fundamentals * Assessed data
Dynamic Chart
Charles River Laboratories International, Inc. Unveils Lentivation Platform to Expedite Lvv-Based Gene Therapy Manufacturing CI
TD Cowen Cuts Charles River Laboratories' Price Target to $209 From $212, Maintains Market Perform Rating MT
Charles River Laboratories International Opens First RightSource Lab in UK MT
Charles River Laboratories International, Inc. Announces Opening of RightSourceSM Laboratory CI
Guggenheim Adjusts Price Target on Charles River Laboratories International to $225 From $255, Maintains Buy Rating MT
UBS Adjusts Charles River Laboratories International Price Target to $250 From $255, Maintains Buy Rating MT
Wells Fargo Adjusts Charles River Laboratories International Price Target to $275 From $280, Maintains Overweight Rating MT
Charles River Laboratories International, Inc. Reaffirms Earnings Guidance for the Year 2023 and Provides Revenue Guidance for the Year 2024 CI
Charles River Laboratories Seeks M&A CI
Transcript : Charles River Laboratories International, Inc. - Analyst/Investor Day CI
Charles River, Related Sciences Team Up to Advance AI-Enabled Drug Discovery Through Logica MT
Charles River Laboratories International, Inc. and Related Sciences Enters Multi- Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica CI
TD Cowen Initiates Coverage on Charles River Laboratories International With Market Perform Rating, $212 Price Target MT
Transcript : Charles River Laboratories International, Inc. Presents at Baird's Global Healthcare Conference 2023, Sep-13-2023 09:05 AM CI
Transcript : Charles River Laboratories International, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 10:10 AM CI
More news
1 day-1.32%
1 week-2.12%
Current month-1.32%
1 month-5.34%
3 months-7.32%
6 months-3.43%
Current year-11.25%
More quotes
1 week
191.00
Extreme 191
198.90
1 month
191.00
Extreme 191
213.04
Current year
181.22
Extreme 181.22
262.00
1 year
181.22
Extreme 181.22
262.00
3 years
181.22
Extreme 181.22
460.21
5 years
95.58
Extreme 95.58
460.21
10 years
44.12
Extreme 44.12
460.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 1991
Director of Finance/CFO 50 2022
Compliance Officer - 2010
Members of the board TitleAgeSince
Chairman 72 1999
Director/Board Member 72 2011
Director/Board Member 77 2007
More insiders
Date Price Change Volume
23-10-02 193.39 -1.32% 523,703
23-09-29 195.98 +0.34% 365,659
23-09-28 195.31 +0.19% 433,619
23-09-27 194.94 +0.26% 403,647
23-09-26 194.44 -1.58% 337,312

Delayed Quote Nyse, October 02, 2023 at 04:00 pm EDT

More quotes
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.5%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development of solutions used in drug manufacturing processes (21%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies; - development and sale of research models and related services (19.5%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies. Net sales break down by source of income between sales of services (77.8%) and sales of products (22.2%). Net sales are distributed geographically as follows: the United States (54.6%), Europe (29.3%), Canada (9.6%), Asia/Pacific (6.3%) and other (0.2%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
195.98USD
Average target price
238.64USD
Spread / Average Target
+21.77%
Consensus
  1. Markets
  2. Equities
  3. Stock Charles River Laboratories International, Inc. - Nyse
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer